{"id":667812,"date":"2023-09-14T09:12:02","date_gmt":"2023-09-14T09:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=667812"},"modified":"2023-09-14T09:12:02","modified_gmt":"2023-09-14T09:12:02","slug":"cystinuria-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-revive-therapeutics-otsuka-pharmaceutical-eloxx-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cystinuria-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-revive-therapeutics-otsuka-pharmaceutical-eloxx-pharmaceuticals_667812.html","title":{"rendered":"Cystinuria Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Revive Therapeutics, Otsuka Pharmaceutical, Eloxx Pharmaceuticals"},"content":{"rendered":"
\n
\"Cystinuria<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Cystinuria Market Insights, Epidemiology and Market Forecast\u2013 2032” report delivers an in-depth understanding of the Cystinuria, historical and forecasted epidemiology as well as the Cystinuria market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.<\/div>\n

DelveInsight’s “Cystinuria Market Insights, Epidemiology and Market Forecast– 2032<\/a><\/strong>” report delivers an in-depth understanding of the Cystinuria, historical and forecasted epidemiology as well as the Cystinuria market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.<\/p>\n

Cystinuria Overview<\/strong><\/p>\n

Cystinuria is an inheritable autosomal recessive disorder of amino acid transport affecting the epithelial cells of the renal tubules and gastrointestinal tract. It is characterized by abnormal concentrations of cystine and the other dibasic amino acids in the urine, resulting in a risk of renal stone formation because of the low solubility of cystine in urine. According to the recent advances in molecular genetics, two genes have been identified as responsible for this disease (SLC3A1 and SLC7A9), but other unknown genes may be involved in cystinuria. We assessed the presence of cystinuria in 2086 consecutive patients with renal stones by using the cyanide-nitroprusside test (Brand’s test). According to our experience, this screening test should be performed in all patients at the onset of renal stone disease in order to avoid a delay in the possible diagnosis of cystinuria. In fact, cystinuric patients often have mixed calculi composed of substances other than cystine that can disguise the presence of cystininuria that is so diagnosed many years after the onset of the initial symptoms.<\/p>\n

\"\"<\/p>\n

Cystinuria Epidemiology Insights<\/strong><\/p>\n